Sironax is a clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases. Founded in 2017, the company has built a diverse pipeline of programs by targeting contributors of aging, degeneration, metabolic dysfunction, and inflammation. 

Sironax is conducting clinical studies with SARM1 inhibitor SIR2501, NAMPT activator SIR4156, and RIPK1 inhibitor SIR9900, in addition to ongoing preclinical research. The company was named to the 2025 Endpoints 11 list of the most promising biotech startups. 

For more information, visit sironax.com.

Sironax

Shefali Agarwal

This department oversees clinical operations, development processes, and medical affairs to ensure effective drug trial execution and compliance.

Clinical Operations and Development

This department oversees the planning, management, and execution of clinical trials and ensures regulatory compliance.

Clinical Operations

This department manages budgeting, accounting, and financial reporting to ensure the organization’s financial health.

Finance Department

This department manages recruitment, employee relations, and organizational development.

Human Resources

This department focuses on cultivating and advancing leadership skills within the organization.

Leadership Development

This department is responsible for advancing scientific knowledge and innovation through research and experimentation.

Sironax

Org chart

Teams

Clinical Operations and Development

Clinical Operations

Finance Department

Human Resources

Leadership Development

Research and Development

Offices

Sironax

Org chart

Teams

Clinical Operations and Development

Clinical Operations

Finance Department

Human Resources

Leadership Development

Research and Development

Offices

Related companies